Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Early-stage Breast Cancer|Hormone Receptor Positive Breast Carcinoma|Invasive Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer
Interventions: DRUG: Anastrozole|PROCEDURE: Therapeutic Conventional Surgery|BIOLOGICAL: Trastuzumab Deruxtecan
Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: Translational Research in Oncology-U.S|Daiichi Sankyo Co., Ltd.